REVIEW article
Front. Aging
Sec. Interventions in Aging
Volume 6 - 2025 | doi: 10.3389/fragi.2025.1638168
Recent Progress in Stem Cell and Immune Cell-Based Interventions for Aging and Age-Related Disorders
Provisionally accepted
- Shanghai Cell Therapy Group Co., Ltd., Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The extension of human lifespan has intensified the demand for developing more effective strategies to enhance quality of life. Age-related physiological decline and associated diseases now constitute significant societal challenges. As scientific understanding of aging mechanisms deepens, targeted intervention in the aging process is becoming increasingly feasible. Emerging evidence suggests that lifespan extension with preserved healthspan can be achieved through metabolic modulation and innovative molecular biology approaches. Notably, cell-based therapies demonstrate substantial antiaging potential via multiple mechanisms including metabolic reprogramming, cellular repair systems, tissue regeneration, senescent cell clearance, and immunomodulation. This has catalyzed the emergence of cellular rejuvenation as a distinct discipline within anti-aging research. This review systematically examines current understanding of aging mechanisms, recent advancements in stem cell/immune cell technologies, and their clinical translation in age-related interventions. We further identify key challenges and future directions in the field, aiming to provide novel insights for extending human healthspan and improving geriatric care.
Keywords: Aging, aging symptoms, aging-related diseases, Stem Cell Therapy, Immune cell therapy
Received: 30 May 2025; Accepted: 11 Jul 2025.
Copyright: © 2025 He, Donglei, Zong, Zhang, Han and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zenghui Xu, Shanghai Cell Therapy Group Co., Ltd., Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.